Chalcogen Or Nitrogen Bonded Indirectly To The Imidazole Ring By Nonionic Bonding Patents (Class 514/399)
  • Patent number: 10273218
    Abstract: The present application relates to compounds of any one of Formulae I, Ia, Ib, Ic, Id, Ie, and If. Compounds of Formula (I) have the structure: wherein A, B, W, Y, Z, R2, R4, R5, R6, Rq and q are as defined herein. The compounds can be used as inhibitors of Bcl-3 and can be used for the treatment of cancer, particularly metastatic cancer.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: April 30, 2019
    Assignee: University College Cardiff Consultants Limited
    Inventors: Andrew David Westwell, Andrea Brancale, Richard William Ernest Clarkson
  • Patent number: 10245257
    Abstract: The present invention provides methods for treating onychomycosis. In certain embodiments, the methods comprise comprising applying a pharmaceutically acceptable formulation containing 10% efinaconazole once a day for a treatment period of at least 36 weeks to the treatment area of an onychomycosis patient (a) without debriding the nail or nail-associated tissue initially or during the treatment period and/or (b) without removing the formulation from the treatment area during the treatment period. In certain embodiments, the formulation also comprises, water, cyclomethicone, diisopropyl adipate, alcohol, C12-15 alkyl lactate, butylated hydroxytoluene, citric acid anhydrous, and disodium edetate.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: April 2, 2019
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Radhakrishnan Pillai, Gordon Dow
  • Patent number: 10232047
    Abstract: The present invention is directed to anti-fungal compositions comprising an anti-fungal agent, an oil and excipients or additives. The compositions of the present invention are devoid of C-11 or greater fatty acids/esters.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: March 19, 2019
    Assignee: VYOME BIOSCIENCES PRIVATE LIMITED
    Inventors: Sudhanand Prasad, Nilu Jain, Sumana Ghosh, Suresh Chawrai
  • Patent number: 10159669
    Abstract: Disclosed are pharmaceutical compositions comprising mdivi-1 and nutlin-3, individually and in combination, for topical or intravitreal ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma, optic neuropathies including Leber Hereditary Optic Neuropathy, arteritic or non-arteritic Ischemic Optic Neuropathy, and retinal artery and vein occlusions.
    Type: Grant
    Filed: March 2, 2010
    Date of Patent: December 25, 2018
    Inventor: Ian H. Chan
  • Patent number: 10004756
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: June 26, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9956238
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as low back pain.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: May 1, 2018
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 9763870
    Abstract: The invention relates to formulations containing liquid ester quats and/or imidazolinium salts and polymer thickeners and to the use thereof.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: September 19, 2017
    Assignee: EVONIK DEGUSSA GMBH
    Inventors: Peter Schwab, Ursula Westerholt, Uta Kortemeier, Jochen Kleinen, Christian Hartung, Hans-Juergen Koehle
  • Patent number: 9545394
    Abstract: Disclosed herein is a method of upregulating regulatory T cells, and treating diseases that would benefit from such upregulation, by administering an alpha-2 receptor agonist.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: January 17, 2017
    Assignee: Allergan, Inc.
    Inventors: Daniel W. Gil, John E. Donello, Veena Viswanath, Lauren M. B. Luhrs
  • Patent number: 9206163
    Abstract: The present invention relates to an improved process for the preparation of Sunitinb. The process involves the activation of 5-((Z)-(5-fluoro-2-oxoindolin-3-ylidene) methyl)-2,4-dimethyl-1 H-pyrrole-3carboxylic acid to corresponding suitable carboxylic acid activating group. The present invention also relates to novel acid addition salts of Sunitinb and preparation thereof.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: December 8, 2015
    Assignee: Laurus Labs Private Ltd.
    Inventors: Sanjay Kumar Dehury, Venkata Lakshmi Narasimha Dammalapati, Venkata Sunil Kumar Indukuri, Seeta Ramanjaneyulu Gorantla
  • Patent number: 9179681
    Abstract: Pesticidal compositions and their uses are disclosed.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: November 10, 2015
    Assignee: Dow AgroSciences LLC
    Inventors: Annette Vitale Brown, Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, Emily Marie Rigsbee, William Thomas Lambert, Noormohamed Niyaz
  • Patent number: 9131692
    Abstract: An antibacterial imidazolium compound, a photocurable coating composition, and an antibacterial coating film includes a compound represented by Chemical Formula 1 shown below or derivatives thereof. In Chemical Formula 1, description of X?, R1 and, R2 is the same as in the detailed description of the invention. The antibacterial imidazolium compound has excellent antibiosis over various strains, and is included in a photocurable coating composition so as to provide an antibacterial coating film by a simple method. Also, in the antibacterial coating film, the antibacterial imidazolium compound is included as a monomer and chemically bonded to a polymer chain, and thus, antibacterial performance can be maintained for a long period of time.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: September 15, 2015
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Man Ho Kim, Kwang Duk Ahn, Mirinae Kim
  • Patent number: 9078895
    Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: July 14, 2015
    Assignees: St. Jude Children's Research Hospital, Flanders Interuniversity Institute for Biotechnology, Universiteit Gent, Leiden University Medical Center
    Inventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
  • Patent number: 9079876
    Abstract: Disclosed are imidazole derivatives as represented by formula (I), and preparation method and use thereof. The compounds can inhibit cyclooxygenase and treat diseases mediated by cyclooxygenase.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: July 14, 2015
    Assignee: Beijing Orbiepharm Co., Ltd.
    Inventor: Jin Li
  • Publication number: 20150133509
    Abstract: The present invention provides a tree trunk injection agent whereby pathogenic fungi and/or pests in trees can be effectively controlled merely by a short-time application in a low chemical dose, and a method for controlling tree diseases using the tree trunk injection agent. According to one embodiment of the present invention, the tree trunk injection agent is obtained by adding, to an aqueous solution of an insecticidal component such as acetamiprid, a hardly soluble fungicidal component such as thiophanate-methyl so as to suspend the hardly soluble fungicidal component, wherein a particle size based on 50% volume of the fungicidal component is 4 ?m or less, or adding thereto at least one fungicidal component selected from a group consisting of triflumizole and metconazole.
    Type: Application
    Filed: April 30, 2013
    Publication date: May 14, 2015
    Applicant: NIPPON SODA CO., LTD.
    Inventors: Takahiro Maekawa, Yasuhiro Omori
  • Publication number: 20150126467
    Abstract: The disclosure relates to use of alginate oligomers to enhance the effects of antifungal agents. The invention provides a method to improve the efficacy of an antifungal agent against a fungus, said method comprising using said antifungal agent together with an alginate oligomer. The fungus may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use together with at least one antifungal agent in treating a subject infected, suspected to be infected, or at risk of infection, with a fungus. In another aspect the method can be used to combat fungal contamination of a site e.g., for disinfection and cleaning purposes.
    Type: Application
    Filed: September 14, 2012
    Publication date: May 7, 2015
    Applicant: AlgiIPharma AS
    Inventors: Edvar Onsøyen, Arne Dessen, David William Thomas, Katja Etel Hill, Hàvard Sletta, Anne Tøndervik, Geir Klinkenberg, Rolf Myrvold
  • Patent number: 9023874
    Abstract: The invention relates to alkylsulfide derivatives compounds of formula I as hereunder depicted or the enantiomers or veterinarily acceptable salts thereof which are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to methods for controlling invertebrate pests by using these compounds and to plant propagation material and to agricultural and veterinary compositions comprising said compounds. wherein U, R1, R2, R3U, X, n and p are defined as in the description.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: May 5, 2015
    Assignee: Merial, Inc.
    Inventors: Sebastian Soergel, Ralph Paulini, Steffen Gross, Carsten Beyer, Matthias Pohlman, Henricus Maria Martinus Bastiaans, Michael Rack, Deborah L. Culbertson, Douglas D. Anspaugh, Sarah Thompson, Vincent Salgado
  • Patent number: 9006278
    Abstract: Controlled release systems release at least one pluribioactive antifungal drug exhibiting at least one additional bioactivity from the group consisting of spermiostatic, antineoplastic, antibacterial, antirestenotic and antiviral activities. The drug release system is designed for use as a spermiostatic contraceptive, intravaginal ringed-mesh which may also exhibit antiviral activity, an in situ-forming implant for treating different forms of cancer and topical film for treating or preventing bacterial and fungal infections.
    Type: Grant
    Filed: January 29, 2011
    Date of Patent: April 14, 2015
    Assignee: Poly-Med, Inc.
    Inventors: Shalaby W. Shalaby, Georgios T. Hilas, Sheila Nagatomi
  • Patent number: 9000017
    Abstract: The present invention relates to combinations of imazalil, or a salt thereof, and silver compounds which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of imazalil, or a salt thereof, together with one or more silver salts selected from silver acetate, silver alginate, silver azide, silver citrate, silver lactate, silver nitrate, silver sulfate, silver chloride, silver thiocyanate, silver-sodium-hydrogen-zirconium phosphate, silver sulfadiazine, silver cyclohexanediacetic acid and disilver 2,5-dichloro-3,6-dihydroxy-2,5-cyclohexadiene-1,4-dione; in respective proportions to provide a synergistic biocidal effect.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: April 7, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Amber Paula Marcella Thys, Jan Pieter Hendrik Bosselaers, Dany Leopold Jozefien Bylemans
  • Patent number: 9000022
    Abstract: Methods of using compounds of the invention, such as compounds of Formulae IIa, IIb, IIc, or IId and pharmaceutically acceptable salts thereof are disclosed. The compounds are useful in treating, preventing, inhibiting or ameliorating the symptoms of a disease or disorder that is modulated or otherwise affected by nuclear receptor activity, or in which nuclear receptor activity is implicated.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: April 7, 2015
    Assignee: Exelixis Patent Company LLC
    Inventors: Brett B. Busch, Brenton T. Flatt, Xiao-Hui Gu, Shao Po Lu, Richard Martin, Raju Mohan, Michael Charles Nyman, Edwin J. Schweiger, William C. Stevens, Jr., Tie-Lin Wang, Yinong Xie
  • Patent number: 8993768
    Abstract: Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment or prevention of infection by human immunodeficiency virus (HIV).
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: March 31, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: John A. Beutler, Stuart F. J. LeGrice, Craig Thomas, Jian-Kang Jiang, Suhman Chung, Jennifer Wilson
  • Patent number: 8993584
    Abstract: Providing a novel control agent for soft rot and a novel control method for the same. A compound having no antibacterial activity against Erwinia carotovora but having a control activity against fungi on soil surface, specifically containing, as the active ingredient, a fungicide comprising any of a strobilurin compound such as azoxystrobin and kresoxim-methyl, an azole compound such as triflumizol, cyazofamid, amisulbrom, and thiophanate-methyl, a carboxamide compound such as penthiopyrad and boscalid, a sulfonamide compound such as flusulfamide, an organic chlorine compound such as chlorothalonil, a dicarboximide compound such as procymidone and iprodione, a phenylpyrrole compound such as fludioxonil, an anilinopyrimidine compound such as mepanipyrim, and a guanidine compound such as iminoctadine is the control agent for plant soft rot, which is applied to plant cultivation soil.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: March 31, 2015
    Assignee: Ishihara Sangyo Kaisha, Ltd.
    Inventors: Koji Sugimoto, Hiroyuki Hayashi
  • Publication number: 20150064232
    Abstract: [Problem] To provide a transdermal absorption preparation exhibiting excellent transdermal absorbability for 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof. [Solution] A transdermal absorption preparation having a support, and a rubber-based adhesive layer that is formed on the surface of the support and contains 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof, the rubber-based adhesive layer further containing oleic acid, capric acid and crotamiton.
    Type: Application
    Filed: March 21, 2013
    Publication date: March 5, 2015
    Inventors: Masato Watanabe, Norihiro Kanayama
  • Patent number: 8962599
    Abstract: Therapeutic compositions comprising substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: February 24, 2015
    Assignee: Antecip Bioventures II LLC
    Inventor: Herriot Tabuteau
  • Publication number: 20150038480
    Abstract: The invention provides methods of preventing, treating or ameliorating autoimmune diseases, such as diabetes and celiac disease, by decreasing the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same.
    Type: Application
    Filed: May 29, 2012
    Publication date: February 5, 2015
    Applicants: UNIVERSITY OF FLORIDA RESERCH FOUNDATION INCORPORTED, THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate
    Inventors: Aaron Michels, Maki Nakayama, David Ostrov
  • Patent number: 8940780
    Abstract: The present invention relates to N-acyl derivatives of amino acids and pharmaceutically acceptable salts thereof wherein n is 2 or 3; and R1 represents or pharmaceutically acceptable salts thereof, to novel processes for preparing the same, to use thereof as anti-allergic, anti-anaphylactic, anti-inflammatory and hypolipidemic agents as well as to a pharmaceutical composition comprising the indicated compounds in an efficient amount and to a method for treating allergic and inflammatory diseases and lipid metabolism disorders: bronchial asthma, allergic rhinitis, pollinoses, seasonal and year-round rhinitis, allergic pneumonitis, atopic dermatitis, psoriasis, urticaria, allergic (including anaphylactic) reactions to insect stings and medicaments, cold allergy, allergic conjunctivitis, atherosclerosis, obesity, ischemic heart and cerebral disease, myocardial infarction and stroke.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: January 27, 2015
    Assignees: Otkrytoe Aktsionernoe Obschestvo Otechestvennye Lekarstva, Vladimir Evgenievich Nebolsin
    Inventors: Vladimir Evgenievich Nebolsin, Tatyana Alexandrovna Kromova, Galina Alexandrovna Zheltukhina, Violetta Leonidovna Kovaleva
  • Publication number: 20150011559
    Abstract: The invention provides methods of treating a bacterial infection in a mammal comprising administering to the mammal a compound of formula I: wherein A, B, and X have any of the meanings defined in the specification; or a pharmaceutically acceptable salt thereof, as well as novel compounds of formula I and salts thereof and pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 11, 2013
    Publication date: January 8, 2015
    Inventors: Edmond J. LaVoie, Ajit Parhi, Daniel S. Pilch, Yongzheng Zhang, Malvika Kaul
  • Publication number: 20150010635
    Abstract: Controlled release particles are obtained by dissolving a hydrophobic antibiotic compound with a hydrophobic polymerizable vinyl monomer to prepare a hydrophobic solution, blending water with an emulsifier to prepare an aqueous emulsifier solution, emulsifying the hydrophobic solution in the aqueous emulsifier solution, and polymerizing the polymerizable vinyl monomer by mini-emulsion polymerization in the presence of a polymerization initiator, thereby producing a polymer containing an antibiotic compound and having an average particle size of below 1 ?m.
    Type: Application
    Filed: December 27, 2012
    Publication date: January 8, 2015
    Applicant: Japan EnviroChemicals, Ltd.
    Inventors: Junji Oshima, Hideaki Inoue
  • Patent number: 8921403
    Abstract: The present invention relates to combinations of imazalil, or a salt thereof, and hydroxypyridones which provide an improved biocidal effect. More particularly, the present invention relates to compositions comprising a combination of imazalil, or a salt thereof, together with one or more hydroxypyridones selected from 1-hydroxy-2-pyridinone, ciclopirox, ciclopirox olamine, piroctone, piroctone olamine and rilopirox in respective proportions to provide a synergistic biocidal effect. Compositions comprising these combinations are useful for the protection of any living or non-living material, such as crops, plants, fruits, seeds, objects made of wood, thatch or the like, engineering material, biodegradable material and textiles against deterioration due to the action of microorganisms such as bacteria, fungi, yeasts, algae, viruses, and the like.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: December 30, 2014
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Jan Pieter Hendrik Bosselaers, Dany Leopold Jozefien Bylemans, Amber Paula Marcella Thys
  • Publication number: 20140377235
    Abstract: The present invention features the use of a synthetic triterpenoid to induce gene expression and differentiation of stem or progenitor cells in the treatment of bone/cartilage diseases or conditions.
    Type: Application
    Filed: September 10, 2014
    Publication date: December 25, 2014
    Inventors: Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Nanjoo Suh, Damian Medici, Pamela Gehron Robey
  • Publication number: 20140371232
    Abstract: Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.
    Type: Application
    Filed: December 18, 2012
    Publication date: December 18, 2014
    Inventors: Zhuorong Li, Xingyue Ji, Situ Xue, Guanghui Zheng, Yuhuan Li, Peizhen Tao, Jiandong Jiang
  • Publication number: 20140371252
    Abstract: Processes for making and using compounds of formula (I): wherein R1, R2, R3, R4a, R4b, R5 and R6 are defined herein, as well as other indene derivatives are disclosed herein. These compounds are disclosed as being useful in treating inflammatory conditions or diseases.
    Type: Application
    Filed: January 23, 2014
    Publication date: December 18, 2014
    Applicant: Aquinox Pharmaceuticals Inc.
    Inventors: Jeffery R. Raymond, Kang Han, Yuanlin Zhou, Yuehua He, Bradley Noren, James Gee Ken Yee
  • Patent number: 8901161
    Abstract: Therapeutic compositions comprising at least two substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: December 2, 2014
    Assignee: Antecip Bioventures II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 8901162
    Abstract: The present disclosure relates to therapeutic compositions comprising substituted imidazoliums having multiple acidic groups. The compounds may be used to treat diseases or conditions such as those associated with bone, cancer, or pain. Compositions, dosage forms, methods of treating diseases or conditions, methods of preparation, and other related embodiments related to the substituted imidazoliums are also described herein.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: December 2, 2014
    Assignee: Antecip Bioventures II LLC
    Inventor: Herriot Tabuteau
  • Publication number: 20140336232
    Abstract: The present invention relates to novel 2-iodoimidazole derivatives, to processes for preparing these compounds, to compositions comprising these compounds and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators.
    Type: Application
    Filed: November 23, 2012
    Publication date: November 13, 2014
    Inventors: Hendrik Helmke, Sebastian Hoffmann, Carl Friedrich Nising, Alexander Sudau, Tomoki Tsuchiya, Jürgen Benting, Peter Dahmen, Ulrike Wachendorff-Neumann, David Bernier, Stephane Brunet, Marie-Claire Grosjean-Cournoyer, Hélène Lachaise, Philippe Rinolfi
  • Publication number: 20140328809
    Abstract: The present invention relates to methods for enhancing differentiation of mesenchymal stem cells into chondrocytes and/or inducing chondrogenesis. The invention also relates to applications in the treatment of diseases which can affect cartilage (chondrodystrophies). The present invention also relates to methods of treatment comprising establishing a population of chondrocytes from a population of mesenchymal stem cells, which have been induced to differentiate with a synthetic triterpenoid, and administering the population of cells to a patient.
    Type: Application
    Filed: November 14, 2012
    Publication date: November 6, 2014
    Inventors: Gordon W. Gribble, Damian Medici, Pamela Gehron Robey, Karen T. Liby, Michael B. Sporn, Nanjoo Suh
  • Patent number: 8877754
    Abstract: The invention relates to new compounds of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: November 4, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Gerald Juergen Roth, Martin Fleck, Heike Neubauer, Bernd Nosse
  • Publication number: 20140315960
    Abstract: The present invention relates to novel depot formulations (prodrugs) comprising an immobility promoting unit linked via an ester to an active pharmaceutical ingredient, i.a. common NSAIDs. The novel depot formulations are suitable for intra-articular injections and are soluble at slightly acidic pH to facilitate ease of injection, and sparingly soluble at physiological pH thereby precipitating at the site of administration. The precipitate will slowly dissolve and the active drug is released from dissolved depot formulation following esterase mediated cleavage of the ester link between the immobility promoting unit and the active pharmaceutical agent.
    Type: Application
    Filed: October 31, 2012
    Publication date: October 23, 2014
    Inventor: Claus Selch LARSEN
  • Patent number: 8865757
    Abstract: Therapeutic compositions comprising at least two substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: October 21, 2014
    Assignee: Antecip Bioventures II LLP
    Inventors: Herriot Tabuteau, Eric K. H. Dinkla
  • Patent number: 8859798
    Abstract: Provided herein are compositions of matter and pharmaceutical compositions thereof, for use in inhibiting the growth of various microbial pathogens, including bacteria, fungi, protozoa, and viral pathogens. Also provided herein are methods of treating microbial diseases/infections and cancer with the compositions. The compositions are additionally useful in wood preservation and food preservation by inhibition of microbial growth.
    Type: Grant
    Filed: July 6, 2007
    Date of Patent: October 14, 2014
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Arkady Mustaev, Natalia Kurepina
  • Patent number: 8852648
    Abstract: A composition and method adapted for delivery of hydrophilic, biologically-active agents are disclosed. The composition can include a reverse microemulsion formed from at least one hydrophilic, biologically-active agent solubilized by a hydrophobic reverse emulsion surfactant in a non-stinging, volatile, hydrophobic solvent. The non-stinging, volatile, hydrophobic solvent is selected from the group consisting of volatile linear and cyclic siloxanes, volatile linear, branched, and cyclic alkanes, volatile fluorocarbons and chlorofluorocarbons, liquid carbon dioxide under pressure, and combinations thereof. The reverse microemulsion can be an optically clear solution.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: October 7, 2014
    Assignee: Rochal Industries, LLP
    Inventors: Joseph Charles Salamone, Xiaoyu Chen, Ann Beal Salamone, Katelyn Elizabeth Reilly
  • Patent number: 8846764
    Abstract: The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (ADPKD), autosomal recessive polycystic kidney disease (ARPKD), ARPKD associated congenital hepatic fibrosis, ARPKD associated Caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-HETE synthesizing enzyme inhibitor or a 20-HETE antagonist to the mammal in an amount sufficient to prevent or treat the disease.
    Type: Grant
    Filed: September 13, 2007
    Date of Patent: September 30, 2014
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: William E. Sweeney, Ellis D. Avner, Richard J. Roman
  • Publication number: 20140288136
    Abstract: Methods are provided for treating or preventing chronic obstructive pulmonary diseases such as emphysema, and fibrotic diseases including heart, liver, kidney and vascular diseases, by administering to a subject a pharmaceutical composition comprising a compound that inhibits cytochrome P450RA or CYP26.
    Type: Application
    Filed: February 23, 2014
    Publication date: September 25, 2014
    Inventors: Lambertus J.W.M Oehlen, Bijoy Panicker
  • Publication number: 20140275198
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver, and more specifically relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A (cytochrome P450A) inhibitor as an active ingredient. According to the present invention, the CYP4A inhibitor suppresses endoplasmic reticulum stress, reduces the blood insulin concentration and suppresses apoptosis of liver cells, and hence exhibits effects in preventing or treating diabetes or fatty liver.
    Type: Application
    Filed: February 11, 2014
    Publication date: September 18, 2014
    Applicant: Korea Basic Science Institute
    Inventors: Gun-Hwa Kim, Soohyun Kim, Jong-Soon Choi, Seung II Kim, Edmond Changkyun Park
  • Publication number: 20140249181
    Abstract: Disclosed are compounds that inhibit RNase H activity of retroviruses, for example, a compound of formula (I) wherein R1, R2, and R3 are as described herein, as well as pharmaceutically acceptable salts, solvates, stereoisomers, and prodrugs thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment or prevention of infection by human immunodeficiency virus (HIV).
    Type: Application
    Filed: May 10, 2012
    Publication date: September 4, 2014
    Applicant: The united States of America, as represented by the Secretary, Department of Health and Human Serv
    Inventors: John A. Beutler, Stuart F.J. LeGrice, Craig Thomas, Jian-Kang Jiang, Suhman Chung, Jennifer Wilson
  • Publication number: 20140248376
    Abstract: The present invention relates to a composition for the treatment of skin and ear infections in humans and animals such as dogs, cats and horses. In particular, the present invention relates to a topical composition comprising acetic acid, an antibacterial and/or an anti-fungal, and preferably also an anti-inflammatory. More specifically, the composition of the present invention is a bandage, bedding, clothing, conditioner, cream, drape, dressing, film, foam, gauze, gel, lotion, mousse, otic solution, pad, patch, serum, shampoo, solution, spray, or wipe for treatment or prevention of skin infections, wherein the composition comprises about 0.1-10% acetic acid, about 0.1-10% boric acid, about 0.01-20% azole, and optionally about 0.01-20% corticosteroid.
    Type: Application
    Filed: May 13, 2014
    Publication date: September 4, 2014
    Applicant: DECHRA VETERINARY PRODUCTS, LLC
    Inventor: Steven A. MELMAN
  • Patent number: 8809333
    Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: August 19, 2014
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Jinshan Michael Chen, Michael Joseph Melnick, Justin Ian Montgomery, Usa Reilly
  • Publication number: 20140228308
    Abstract: Formulations for the oral administration of therapeutic agents, methods for administering therapeutic agents using the formulations, and methods for treating conditions and diseases using the formulations.
    Type: Application
    Filed: November 22, 2013
    Publication date: August 14, 2014
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Kishor M. Wasan, Ellen K. Wasan
  • Publication number: 20140221922
    Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: POLY-MED, INC.
    Inventors: Shalaby W. Shalaby, David Ingram, Georgios Hilas, Sheila Nagatomi
  • Publication number: 20140220152
    Abstract: Disclosed herein is a non-human animal model of protein aggregation cardiomyopathy. Also disclosed are compositions and methods of treating or preventing a condition in a subject caused or exacerbated by reductive stress. Also disclosed are compositions and methods of predicting, detecting, or monitoring reductive stress in a subject.
    Type: Application
    Filed: September 12, 2013
    Publication date: August 7, 2014
    Applicant: University of Utah Research Foundation
    Inventors: Ivor J. Benjamin, Namakal S. Rajasekaran, Thomas P. Kennedy
  • Patent number: RE45173
    Abstract: The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17?-hydroxylase/C17,20-lyase inhibitors.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: September 30, 2014
    Assignee: Novartis AG
    Inventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gunmadi, Saumitra Sengupta